Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits.
To assess the potential efficacy of mechano growth factor (MGF) for bone injury, we firstly investigated the effects of growth factors, including MGF, its E peptide (a short 24-amino acid C-terminal peptide, MGF-Ct24E), and insulin-like growth factor 1(IGF-1) on MC3T3-E1 osteoblast-like cell proliferation. MGF-Ct24E had the highest pro-proliferation activity among three growth factors, which was 1.4 times greater than that of IGF-1. Moreover, MGF-Ct24E promoted cell proliferation by inducing cell cycle arrest in the S and G(2)/M phase of the cell cycle, but also mainly by the activation of the MAPK-Erk1/2 pathway. In vivo, a 5-mm segmental bone defect in the radius of 27 rabbits was treated with MGF-Ct24E by two doses (28.5 and 57 μg /kg body weight) vs. non-growth factor injection for five consecutive days postoperatively. The cumulative rate of radiographically healed defects and histological scores of bone defect-healing revealed a statistical difference between high-dose treatment and non treatment (p < 0.01), which showed the treatment promoted defect healing. This report is the first to demonstrate that MGF-Ct24E possesses positive effects on osteoblast proliferation and bone-defect healing, suggesting a new strategy in fracture healing.
Ministry of Education, Key Laboratory of Biorheological Science and Technology, Research Center of Bioinspired Materials, Science and Engineering of National 985 Project program of China, Chongqing University, Chongqing, China. dengmoyuan@yahoo.cn
Moyuan
M
Deng
Bingbing
B
Zhang
Ke
K
Wang
Feng
F
Liu
Hualiang
H
Xiao
Jianhua
J
Zhao
Peng
P
Liu
Yuxiao
Y
Li
Fuchun
F
Lin
Yuanliang
Y
Wang
D000818:Animals; D001861:Bone Regeneration / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D004247:DNA / Q000096:biosynthesis; D004195:Disease Models, Animal; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D020935:MAP Kinase Signaling System / Q000187:drug effects; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism; D010006:Osteoblasts / Q000187:drug effects* / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects* / Q000502:physiology; D011817:Rabbits; D014945:Wound Healing / Q000187:drug effects / Q000502:physiology
C523997:mechano-growth factor E, human; D007334:Insulin-Like Growth Factor I; D004247:DNA; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3